Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

ls and communications pathways in cancer, we are improving our ability to effectively treat the disease while avoiding the toxicities of chemotherapy and potential relapse," said John C. Byrd, MD, lead author and Director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute in Columbus. "If we can replicate these high survival rates and good tolerability with ibrutinib through larger scale Phase III studies, we may find it to be an extremely valuable new therapy for not just elderly, but for all CLL patients."

Dr. Byrd will present this study in an oral presentation on Sunday, December 9, at 5:00 p.m. EST at the Georgia World Congress Center in Thomas Murphy Ballroom 4, Level 5, Building B.

The BTK Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab is Well−Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients [Abstract 187]

The combination of the novel investigational agent ibrutinib with an established therapeutic antibody, rituximab, may present a safer and more effective option than the current standard chemotherapy-based treatment regimen for patients with high-risk CLL.

While current chemotherapy-based treatment options for CLL patients are effective, they come with toxic side effects that are challenging for elderly patients. Physicians have long awaited new options that offer better tolerability. Ibrutinib is designed to selectively target leukemia cell growth, with the aim of effectively treating the disease without the toxicities of chemotherapy. Data from earlier studies of ibrutinib have shown it to be equally effective in both low- and high-risk CLL.

High-risk CLL patients typically have unfavorable responses to standard CLL therapies and a dismal outcome. S
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Insuranceragents.info has released a new blog post explaining ... vulnerable family members. , Life insurance plans provide important ... family should always carry a life insurance policy as ... of the family. , Clients can choose from ... temporary coverage or from a permanent policy. No medical ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 ... networking and relationship-marketing firm, announced today the ... Executive® and Project of the Year Awards ... makers representing organizations in financial services, commercial, ... large-scale technology endeavors that address key issues ...
(Date:10/1/2014)... Between 23 million and 50 million ... to figures from the National Institutes of Health (NIH) ... many of them have something else in common: They ... disease. Gluten Free Therapeutics, makers of CeliVites ... disease by publishing a series of blog posts aimed ...
(Date:10/1/2014)... October 01, 2014 Scientists at the ... drugs that target immune system proteins has the power ... just posted details of the new study on their ... , Researchers in the UWA School of Pathology ... drugs to mice with mesothelioma with promising results. ...
(Date:10/1/2014)... October 01, 2014 Woodland Hills ... to a group of dental specialists who treat full ... Spain city of Oviedo. Dr. Reshad of the Anacapa ... with clients on two continents, will give a full-day ... full mouth reconstruction. , “These specialists want to improve ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4
... 13 Thomson Reuters announced,today that St. Peter,s Hospital ... -- such as increasing its discharge instruction,compliance for heart ... percent in first-quarter 2008., St. Peter,s Hospital, part ... of only 10 hospitals in the nation named for ...
... Utah, Oct. 13 Nutraceutical,International Corporation (Nasdaq: ... Cory McQueen, Vice President and Chief Financial Officer,are ... on Wednesday,October 15, 2008 at the Canaccord Adams ... scheduled for 2:30 PM Eastern,Time that day and ...
... the combination of low plasma levels of antioxidants and blue ... of the eye disease age-related macular degeneration (AMD), according to ... Ophthalmology , one of the JAMA/Archives journals. , ... the authors write as background information in the article. "While ...
... Oct. 13 Today,s autism research draws on ... magnetic,resonance imaging (fMRI) to neural development. At the ... in Autism," 16 of,the world,s most prominent autism ... disorder and discuss the direction of future,study that ...
... KEEP WARM THIS WINTER WITH THE VIPER RESPONDER LE SPECIAL ... EDITION VEHICLE SECURITY & REMOTE START SYSTEM, ... DEI Holdings Inc. (Nasdaq: DEIX ), has joined,the fight ... 2-Way Vehicle Security & Remote Start systems from Viper,supporting Susan ...
... interruption to shipments or service to new or ... Cardiac Science,Corporation (Nasdaq: CSCX ) announced today ... action of certain automated external,defibrillators (AEDs) manufactured between ... this time frame may have a component whose ...
Cached Medicine News:Health News:St. Peter's Hospital of Albany Improves Core Measures Processes 2Health News:St. Peter's Hospital of Albany Improves Core Measures Processes 3Health News:Nutraceutical to Present at Canaccord Adams Healthy Living Conference 2Health News:Nutraceutical to Present at Canaccord Adams Healthy Living Conference 3Health News:Sunlight exposure plus low antioxidant levels may place older adults at risk for eye disease 2Health News:Carnegie Mellon International Autism Symposium to Feature Groundbreaking Research, Oct. 17-18 2Health News:Supporting Susan G. Komen for the Cure(R) During National Breast Cancer Awareness Month 2Health News:Supporting Susan G. Komen for the Cure(R) During National Breast Cancer Awareness Month 3Health News:Cardiac Science Initiates Voluntary Field Corrective Action of Certain AEDs 2Health News:Cardiac Science Initiates Voluntary Field Corrective Action of Certain AEDs 3
(Date:9/30/2014)... STUDY OBJECTIVES The objective of ... an overview of the current and future characteristics ... key objective is to present a comprehensive analysis ... important tool in the treatment of various diseases. ... within the protein therapeutics market, which includes peptide ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Aileron Therapeutics, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
(Date:9/30/2014)... 2014  Decision Resources Group finds that the Asia ... China , India , ... rate through 2023. Dental implant procedure volumes will grow as physicians ... Other key findings from Decision Resources Group,s coverage of ... , Dental implant penetration: Penetration of dental implants among ...
Breaking Medicine Technology:Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3
... TITUSVILLE, N.J., Aug. 21 The U.S. ... letter regarding the New Drug Application (NDA) for carisbamate, ... , , The NDA, filed in ... Development, L.L.C. (J&JPRD) on behalf of Ortho-McNeil-Janssen Pharmaceuticals, Inc. ...
... FORT LAUDERDALE, Fla., Aug. 20 OmniComm Systems, Inc. (OTC ... the EDC marketplace, today announced that Impax Pharmaceuticals, the brand ... TrialMaster EDC solution for conducting a Phase III study in ... clinical trial there can be significant challenges in getting trial ...
Cached Medicine Technology:FDA Issues Complete Response Letter for Carisbamate 2FDA Issues Complete Response Letter for Carisbamate 3Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease 2Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease 3
Weight is evenly distributed by fully adjustable velcro straps that cross in the back. Adjustable back velcro keeps apron snug....
6" wide elastic belt transfers the apron weight off the shoulders to the hips making this apron the most comfortable for long procedures. Adjustable. Velcro keeps apron snug....
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
... The NS272 is a fully featured ... is used to monitor neuromuscular blocks during ... nerve location during regional anesthesia. , ... are the only known PNS that can ...
Medicine Products: